C07K 14/565
Ifn-beta
Official title: IFN-beta
C07K14/565 (Ifn-beta) appears on 350 US grants and 411 published applications in this corpus.
Search patents in C07K- Granted patents
- 350
- Published applications
- 411
- Assignees
- 205
- Inventors
- 799
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 2 | 0 |
| 1981 | 5 | 0 |
| 1982 | 4 | 0 |
| 1983 | 1 | 0 |
| 1984 | 9 | 0 |
| 1985 | 6 | 0 |
| 1986 | 4 | 0 |
| 1987 | 4 | 0 |
| 1988 | 10 | 0 |
| 1989 | 6 | 0 |
| 1990 | 5 | 0 |
| 1991 | 6 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 7 | 0 |
| 1996 | 8 | 0 |
| 1997 | 5 | 0 |
| 1998 | 5 | 0 |
| 1999 | 7 | 0 |
| 2000 | 4 | 0 |
| 2001 | 7 | 0 |
| 2002 | 2 | 4 |
| 2003 | 6 | 10 |
| 2004 | 4 | 14 |
| 2005 | 1 | 18 |
| 2006 | 6 | 13 |
| 2007 | 10 | 11 |
| 2008 | 10 | 24 |
| 2009 | 12 | 19 |
| 2010 | 13 | 17 |
| 2011 | 10 | 17 |
| 2012 | 10 | 10 |
| 2013 | 14 | 11 |
| 2014 | 7 | 17 |
| 2015 | 16 | 23 |
| 2016 | 13 | 26 |
| 2017 | 14 | 23 |
| 2018 | 11 | 13 |
| 2019 | 17 | 10 |
| 2020 | 13 | 23 |
| 2021 | 6 | 19 |
| 2022 | 10 | 21 |
| 2023 | 6 | 18 |
| 2024 | 6 | 24 |
| 2025 | 11 | 14 |
| 2026 | 6 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment using cytokine encoding RNA18 Aug 2026US 12,708,643 B2BioNTech SE
- Activatable cytokine polypeptides and methods of use thereof5 May 2026US 12,617,829 B2Werewolf Therapeutics, Inc.
- 5T4 single domain antibodies and therapeutic compositions thereof31 Mar 2026US 12,590,169 B2Inhibrx Biosciences, Inc.
- Recombinant influenza viruses comprising truncated NS1 fusion proteins24 Mar 2026US 12,582,708 B2I.D.Bio.
- Fibroblast activation protein binding agents and use thereof24 Mar 2026US 12,583,941 B2Orionis Biosciences BV
- Genetically engineered cd4 t-cells for in situ synthesis of proteins8 Oct 2026US 2026/0308515 A1SRI International
- Target protein expression platform using viral nucleocapsid10 Sep 2026US 2026/0265307 A1University-Industry Foundation, Yonsei University
- Activatable cytokine polypeptides and methods of use thereof27 Aug 2026US 2026/0250345 A1Werewolf Therapeutics, Inc.
- Encrypted RNA and Methods of Its Use27 Aug 2026US 2026/0250710 A1Autonomous Therapeutics, Inc.
- Recombinant oncolytic virus and use thereof16 Jul 2026US 2026/0199415 A1Joint Biosciences (Sh) Ltd.
Most cited
By later US patents
- Human recombinant interleukin-2 muteins297US 4,518,584 ACetus Corporation · 1985
- Covalently linked polypeptide cell modulators269US 4,935,233 AG. D. Searle & Co. · 1990
- Human recombinant cysteine depleted interferon-.beta. muteins253US 4,588,585 ACetus Corporation · 1986
- Immunoglobulin chimeric monomer-dimer hybrids215US 7,404,956 B2Syntonix Pharmaceuticals, Inc. · 2008
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006